# Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

> **NCT00057447** · PHASE1,PHASE2 · TERMINATED · sponsor: **InterMune** · enrollment: 24 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Interferon Gamma-1b
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00057447
- **Lead sponsor:** InterMune
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-03
- **Primary completion:** —
- **Final completion:** 2004-06
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** administrative reasons
- **Last updated:** 2007-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00057447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00057447, "Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00057447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*